- Published on
Emergency and Acute Medicine – Mushroom Poisoning
Mushroom poisoning encompasses a wide spectrum of toxic syndromes caused by ingestion of wild or contaminated mushrooms, with clinical severity ranging from mild, self-limited gastrointestinal upset to fulminant hepatic or renal failure and death. Toxicity depends on the mushroom species, the specific toxin involved, the quantity ingested, and the timing of presentation. The most lethal poisonings are associated with delayed symptom onset, particularly those involving amanitin-containing mushrooms.
Amanitin and phalloidin toxins are found in species such as *Amanita phalloides* (death cap), *Amanita virosa* and *Amanita verna* (destroying angels), and some *Galerina* species. These cyclopeptide toxins inhibit RNA polymerase II, resulting in cellular death of gastrointestinal epithelium, hepatocytes, and renal tubular cells. Symptoms are characteristically delayed for 6–36 hours and begin with severe nausea, vomiting, abdominal pain, and diarrhea, followed by a transient asymptomatic phase. Progressive hepatic failure, coagulopathy, hypoglycemia, renal failure, and death may occur within days, making this the most dangerous category of mushroom poisoning.
Gyromitrin poisoning, most commonly from *Gyromitra esculenta* (false morels), interferes with pyridoxal phosphate metabolism and causes neurologic, hepatic, and hematologic toxicity. Early gastrointestinal symptoms are followed by weakness, confusion, seizures, coma, and possible liver injury. Muscarine-containing mushrooms such as *Inocybe* and *Clitocybe* species cause rapid-onset cholinergic toxicity, including salivation, lacrimation, diarrhea, bronchoconstriction, bradycardia, and miosis, typically within one hour of ingestion.
Coprine toxicity, seen with *Coprinus atramentarius* (inky cap), produces a disulfiram-like reaction when alcohol is consumed, leading to flushing, nausea, vomiting, palpitations, and diaphoresis. Ibotenic acid and muscimol, found in *Amanita muscaria* and *Amanita pantherina*, act as GABA agonists and cause hallucinations, ataxia, dysarthria, somnolence, and, in children, seizures. Psilocybin and psilocin-containing mushrooms cause serotonergic effects with hallucinations and perceptual disturbances that typically resolve within hours.
Other toxic syndromes include gastric irritant mushrooms that cause early-onset nausea, vomiting, and diarrhea; orellanine-containing *Cortinarius* species and *Amanita smithiana*, which cause delayed and often severe renal failure days to weeks after ingestion; and *Tricholoma equestre*, associated with acute rhabdomyolysis and renal injury.
Diagnosis relies heavily on history, including time of ingestion, symptom onset, number of mushrooms consumed, preparation method, coingestants, alcohol use, and whether others who ate the same mushrooms are symptomatic. Physical examination focuses on vital signs, mental status, abdominal findings, neurologic deficits, and signs of cholinergic or serotonergic toxicity. Exact mycologic identification is uncommon, but any remaining mushrooms should be stored in a brown paper bag and photographed for expert consultation through poison control.
Laboratory evaluation includes complete blood count, electrolytes, renal function tests, liver function tests, coagulation studies, creatine phosphokinase, glucose, and urinalysis. Serial testing is critical in delayed-onset poisonings. Imaging is generally supportive, and specialized testing such as spore prints requires expert interpretation.
Management begins with airway, breathing, and circulation stabilization, intravenous fluids, and close monitoring. Activated charcoal is recommended early in most cases, particularly with suspected amanitin ingestion, and may be repeated. Poison control consultation is essential in all suspected mushroom poisonings. Amanitin toxicity requires aggressive supportive care, correction of hypoglycemia and coagulopathy, consideration of N-acetylcysteine, silibinin or penicillin G when available, and early liver transplant evaluation for signs of hepatic failure. Gyromitrin toxicity is treated with benzodiazepines for seizures and pyridoxine for severe neurologic symptoms. Muscarinic toxicity responds to atropine. Most other syndromes are managed with supportive care, benzodiazepines for agitation or seizures, and careful monitoring for complications.
All symptomatic patients, particularly those with delayed symptom onset, persistent vomiting, neurologic symptoms, or laboratory evidence of hepatic or renal injury, require hospital admission. Intensive care and early transfer to a tertiary center are indicated for amanitin poisoning or evolving organ failure. Asymptomatic patients may be discharged after a period of observation if reliable follow-up is assured.
A key clinical principle is that delayed onset of symptoms beyond six hours strongly suggests a potentially life-threatening toxin. Early consultation with poison control and timely referral for transplant evaluation when indicated are critical to improving outcomes in severe mushroom poisoning.
Mushroom poisoning encompasses a wide spectrum of toxic syndromes caused by ingestion of wild or contaminated mushrooms, with clinical severity ranging from mild, self-limited gastrointestinal upset to fulminant hepatic or renal failure and death. Toxicity depends on the mushroom species, the specific toxin involved, the quantity ingested, and the timing of presentation. The most lethal poisonings are associated with delayed symptom onset, particularly those involving amanitin-containing mushrooms.
Amanitin and phalloidin toxins are found in species such as *Amanita phalloides* (death cap), *Amanita virosa* and *Amanita verna* (destroying angels), and some *Galerina* species. These cyclopeptide toxins inhibit RNA polymerase II, resulting in cellular death of gastrointestinal epithelium, hepatocytes, and renal tubular cells. Symptoms are characteristically delayed for 6–36 hours and begin with severe nausea, vomiting, abdominal pain, and diarrhea, followed by a transient asymptomatic phase. Progressive hepatic failure, coagulopathy, hypoglycemia, renal failure, and death may occur within days, making this the most dangerous category of mushroom poisoning.
Gyromitrin poisoning, most commonly from *Gyromitra esculenta* (false morels), interferes with pyridoxal phosphate metabolism and causes neurologic, hepatic, and hematologic toxicity. Early gastrointestinal symptoms are followed by weakness, confusion, seizures, coma, and possible liver injury. Muscarine-containing mushrooms such as *Inocybe* and *Clitocybe* species cause rapid-onset cholinergic toxicity, including salivation, lacrimation, diarrhea, bronchoconstriction, bradycardia, and miosis, typically within one hour of ingestion.
Coprine toxicity, seen with *Coprinus atramentarius* (inky cap), produces a disulfiram-like reaction when alcohol is consumed, leading to flushing, nausea, vomiting, palpitations, and diaphoresis. Ibotenic acid and muscimol, found in *Amanita muscaria* and *Amanita pantherina*, act as GABA agonists and cause hallucinations, ataxia, dysarthria, somnolence, and, in children, seizures. Psilocybin and psilocin-containing mushrooms cause serotonergic effects with hallucinations and perceptual disturbances that typically resolve within hours.
Other toxic syndromes include gastric irritant mushrooms that cause early-onset nausea, vomiting, and diarrhea; orellanine-containing *Cortinarius* species and *Amanita smithiana*, which cause delayed and often severe renal failure days to weeks after ingestion; and *Tricholoma equestre*, associated with acute rhabdomyolysis and renal injury.
Diagnosis relies heavily on history, including time of ingestion, symptom onset, number of mushrooms consumed, preparation method, coingestants, alcohol use, and whether others who ate the same mushrooms are symptomatic. Physical examination focuses on vital signs, mental status, abdominal findings, neurologic deficits, and signs of cholinergic or serotonergic toxicity. Exact mycologic identification is uncommon, but any remaining mushrooms should be stored in a brown paper bag and photographed for expert consultation through poison control.
Laboratory evaluation includes complete blood count, electrolytes, renal function tests, liver function tests, coagulation studies, creatine phosphokinase, glucose, and urinalysis. Serial testing is critical in delayed-onset poisonings. Imaging is generally supportive, and specialized testing such as spore prints requires expert interpretation.
Management begins with airway, breathing, and circulation stabilization, intravenous fluids, and close monitoring. Activated charcoal is recommended early in most cases, particularly with suspected amanitin ingestion, and may be repeated. Poison control consultation is essential in all suspected mushroom poisonings. Amanitin toxicity requires aggressive supportive care, correction of hypoglycemia and coagulopathy, consideration of N-acetylcysteine, silibinin or penicillin G when available, and early liver transplant evaluation for signs of hepatic failure. Gyromitrin toxicity is treated with benzodiazepines for seizures and pyridoxine for severe neurologic symptoms. Muscarinic toxicity responds to atropine. Most other syndromes are managed with supportive care, benzodiazepines for agitation or seizures, and careful monitoring for complications.
All symptomatic patients, particularly those with delayed symptom onset, persistent vomiting, neurologic symptoms, or laboratory evidence of hepatic or renal injury, require hospital admission. Intensive care and early transfer to a tertiary center are indicated for amanitin poisoning or evolving organ failure. Asymptomatic patients may be discharged after a period of observation if reliable follow-up is assured.
A key clinical principle is that delayed onset of symptoms beyond six hours strongly suggests a potentially life-threatening toxin. Early consultation with poison control and timely referral for transplant evaluation when indicated are critical to improving outcomes in severe mushroom poisoning.
0 Comments
